Fifteen warning letters dispatched by the US Food and Drug Administration in late November illustrate a key challenge companies face in marketing cannabidiol (CBD)-infused cosmetic products.
Amid soaring global interest in all things cannabis and relaxed laws enabling wider use of the plant and increased research...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?